Tumour metabolism: Translating the undruggable target
Nature Reviews Cancer 16, 675 (2016).
doi:10.1038/nrc.2016.107
Author: Anna Dart
Three studies demonstrate the preclinical potential of a novel class of hypoxia-inducible factor 2α (HIF2α) antagonists in the treatment of von Hippel–Lindau (pVHL)-deficient clear cell renal cell carcinoma.
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Anna Dart Tags: Research Highlight Source Type: research
More News: Cancer & Oncology